COSMIC: somatic cancer genetics at high-resolution - PubMed (original) (raw)
. 2017 Jan 4;45(D1):D777-D783.
doi: 10.1093/nar/gkw1121. Epub 2016 Nov 28.
David Beare 2, Harry Boutselakis 2, Sally Bamford 2, Nidhi Bindal 2, John Tate 2, Charlotte G Cole 2, Sari Ward 2, Elisabeth Dawson 2, Laura Ponting 2, Raymund Stefancsik 2, Bhavana Harsha 2, Chai Yin Kok 2, Mingming Jia 2, Harry Jubb 2, Zbyslaw Sondka 2, Sam Thompson 2, Tisham De 2, Peter J Campbell 2
Affiliations
- PMID: 27899578
- PMCID: PMC5210583
- DOI: 10.1093/nar/gkw1121
COSMIC: somatic cancer genetics at high-resolution
Simon A Forbes et al. Nucleic Acids Res. 2017.
Abstract
COSMIC, the Catalogue of Somatic Mutations in Cancer (http://cancer.sanger.ac.uk) is a high-resolution resource for exploring targets and trends in the genetics of human cancer. Currently the broadest database of mutations in cancer, the information in COSMIC is curated by expert scientists, primarily by scrutinizing large numbers of scientific publications. Over 4 million coding mutations are described in v78 (September 2016), combining genome-wide sequencing results from 28 366 tumours with complete manual curation of 23 489 individual publications focused on 186 key genes and 286 key fusion pairs across all cancers. Molecular profiling of large tumour numbers has also allowed the annotation of more than 13 million non-coding mutations, 18 029 gene fusions, 187 429 genome rearrangements, 1 271 436 abnormal copy number segments, 9 175 462 abnormal expression variants and 7 879 142 differentially methylated CpG dinucleotides. COSMIC now details the genetics of drug resistance, novel somatic gene mutations which allow a tumour to evade therapeutic cancer drugs. Focusing initially on highly characterized drugs and genes, COSMIC v78 contains wide resistance mutation profiles across 20 drugs, detailing the recurrence of 301 unique resistance alleles across 1934 drug-resistant tumours. All information from the COSMIC database is available freely on the COSMIC website.
© The Author(s) 2016. Published by Oxford University Press on behalf of Nucleic Acids Research.
Figures
Figure 1.
The front page of COSMIC provides easy ways to search and navigate the database; various tools are available for different perspectives on similar data, and multiple descriptive pages detail data curation procedures and current contents.
Figure 2.
The main Gene Analysis histogram summarises all mutation content across a single gene, in this case gene ABL1. From top-to-bottom, histograms represent mutation recurrence, at each nucleotide/amino acid position, divided into separate segments for single nucleotide substitutions, multinucleotide substitutions, insertions, deletions, copy number gain/loss, gene over/under-expression and CpG hyper/hypo-methylation. Mutation recurrence across the tyrosine kinase domain (highlighted in purple) indicates that this, when mutated, is the key region driving cancer.
Figure 3.
Several named therapeutics have been described treating ABL1-driven cancers, and many studies have reported novel mutations causing resistance to these therapies. This histogram shows a long list of mutations associated with resistance to named therapeutics, with a histogram bar showing their recurrence.
Figure 4.
COSMIC has grown rapidly in recent years, as larger numbers of genes are curated, and additional mutation mechanisms are encompassed. The graphic shows a simple representation of the size of the database supporting the COSMIC website from 2010 to 2016 (gzipped Oracle dmp file, in Mb).
Similar articles
- COSMIC: High-Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer.
Forbes SA, Beare D, Bindal N, Bamford S, Ward S, Cole CG, Jia M, Kok C, Boutselakis H, De T, Sondka Z, Ponting L, Stefancsik R, Harsha B, Tate J, Dawson E, Thompson S, Jubb H, Campbell PJ. Forbes SA, et al. Curr Protoc Hum Genet. 2016 Oct 11;91:10.11.1-10.11.37. doi: 10.1002/cphg.21. Curr Protoc Hum Genet. 2016. PMID: 27727438 - COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer.
Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, Kok CY, Jia M, Ewing R, Menzies A, Teague JW, Stratton MR, Futreal PA. Forbes SA, et al. Nucleic Acids Res. 2010 Jan;38(Database issue):D652-7. doi: 10.1093/nar/gkp995. Epub 2009 Nov 11. Nucleic Acids Res. 2010. PMID: 19906727 Free PMC article. - COSMIC: exploring the world's knowledge of somatic mutations in human cancer.
Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, Kok CY, Jia M, De T, Teague JW, Stratton MR, McDermott U, Campbell PJ. Forbes SA, et al. Nucleic Acids Res. 2015 Jan;43(Database issue):D805-11. doi: 10.1093/nar/gku1075. Epub 2014 Oct 29. Nucleic Acids Res. 2015. PMID: 25355519 Free PMC article. - Cytogenetic Resources and Information.
De Braekeleer E, Huret JL, Mossafa H, Dessen P. De Braekeleer E, et al. Methods Mol Biol. 2017;1541:311-331. doi: 10.1007/978-1-4939-6703-2_25. Methods Mol Biol. 2017. PMID: 27910033 Review. - Oncogenomic portals for the visualization and analysis of genome-wide cancer data.
Klonowska K, Czubak K, Wojciechowska M, Handschuh L, Zmienko A, Figlerowicz M, Dams-Kozlowska H, Kozlowski P. Klonowska K, et al. Oncotarget. 2016 Jan 5;7(1):176-92. doi: 10.18632/oncotarget.6128. Oncotarget. 2016. PMID: 26484415 Free PMC article. Review.
Cited by
- Tumor suppressor ACER1 correlates with prognosis and Immune Infiltration in head and neck squamous cell carcinoma.
Liu Z, Yang X, Chen S, Jia W, Qian Y, Zhang M, Fang T, Liu H, Yang H. Liu Z, et al. Sci Rep. 2024 Nov 14;14(1):28039. doi: 10.1038/s41598-024-78663-1. Sci Rep. 2024. PMID: 39543336 Free PMC article. - COADREADx: A comprehensive algorithmic dissection of colorectal cancer unravels salient biomarkers and actionable insights into its discrete progression.
Palaniappan A, Muthamilselvan S, Sarathi A. Palaniappan A, et al. PeerJ. 2024 Oct 28;12:e18347. doi: 10.7717/peerj.18347. eCollection 2024. PeerJ. 2024. PMID: 39484215 Free PMC article. - Deciphering Cancer Complexity: Integrative Proteogenomics and Proteomics Approaches for Biomarker Discovery.
Rao R, Gulfishan M, Kim MS, Kashyap MK. Rao R, et al. Methods Mol Biol. 2025;2859:211-237. doi: 10.1007/978-1-0716-4152-1_12. Methods Mol Biol. 2025. PMID: 39436604 Review. - High WEE1 expression is independently linked to poor survival in multiple myeloma.
Simhal AK, Firestone R, Oh JH, Avutu V, Norton L, Hultcrantz M, Usmani SZ, Maclachlan KH, Deasy JO. Simhal AK, et al. bioRxiv [Preprint]. 2024 Sep 24:2024.09.20.613788. doi: 10.1101/2024.09.20.613788. bioRxiv. 2024. PMID: 39386721 Free PMC article. Preprint. - Design of linked-domain protein inhibitors of UBE2D as tools to study cellular ubiquitination.
Bukhari Z, Gu L, Nederstigt AE, Cope LJ, Bolhuis DL, Harvey K, Allen T, Hill S, Yang Y, Lawson G, Lu C, Tran T, Pineda L, Low L, Chiang A, Song J, Fong MV, Rangel VM, Chan WK, Kleiger G, Goldfarb D, Vierra CA, Brown NG, Harrison JS. Bukhari Z, et al. bioRxiv [Preprint]. 2024 Sep 2:2024.09.02.610852. doi: 10.1101/2024.09.02.610852. bioRxiv. 2024. PMID: 39282319 Free PMC article. Preprint.
References
- Forbes S.A., Beare D., Bindal N., Bamford S., Ward S., Cole C.G., Jia M., Kok C., Boutselakis H., De T., et al. COSMIC: High-Resolution Cancer Genetics Using the Catalogue of Somatic Mutations in Cancer. Curr. Protoc. Hum. Genet. 2016;91:10.11.1–10.11.37. - PubMed
- Collins F.S., Barker A.D. Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. Sci. Am. 2007;296:50–57. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources